Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Wake Forest University Health Sciences
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02166255CT.gov APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| apn401 (this asset) | Wake Forest University Health Sciences | P1 | CC · 47 |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| Cediranib | M.D. Anderson Cancer Center | P2 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Irinotecan | Melanoma and Skin Cancer Trials Limited | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Iovance Biotherapeutics, Inc. | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for apn401
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P1 | CCC · 52 |
| Melanoma | — | P1 | CC · 47 |
| Renal Cell Carcinoma | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. apn401 in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/apn401-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →